The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell

doi:10.3748/wjg.v8.i4.596

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3349)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

383

HTML

2522

Figures (1-1)

231

Tables (1-7)

213

Sum=3349

Aug 15, 2002 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Aug 15, 2002; 8(4): 596-601
Published online Aug 15, 2002. doi: 10.3748/wjg.v8.i4.596

Table 1 Dose-effect of KDR ASODN on HGCC and HVEC for 48 h (n = 8, ¯x ± s)

KDR ASODN dose/(μmol/L)	Inhibitory rate of cell proliferation (%)
KDR ASODN dose/(μmol/L)	HGCC	HVEC
0 (control)	0	0
0.5	21.32^b	0
1	28.31^b	15.33^b
5	34.56^b	30.53^b
10	45.59^b	39.67^b
15	55.35^b	54.83^b
20	50.74^b	48.79^b

^bP < 0.01 vs control.

Table 2 Time-effect of 15 μmol/L KDR ASODN on HGCC and HVEC (n = 8, ¯x ± s)

KDR ASODN action time/h	Inhibitory rate of cell proliferation (%)
KDR ASODN action time/h	HGCC	HVEC
0 (control)	0	0
3	16.41^b	0
6	18.99^b	6.67^b
12	28.96^b	10.36^b
24	38.90^b	37.52^b
48	55.35^b	54.83^b
72	50.45^b	46.18^b

^bP < 0.01 vs control.

Table 3 Difference between the effects of KDR ASODN and SODN, MODN (n = 8, ¯x ± s)

Types of KDR ODN	Inhibitory rate of cell proliferation (%)
Types of KDR ODN	HGCC	HVEC
No ODN (control)	0	0
ASODN	45.07^b	31.18^b
SODN	3.15^d	2.61^d
MODN	2.88^d	2.02^d

^bP < 0.01, vs control.

^dP < 0.01, vs ASODN group.

Table 4 Expression of KDR mRNA and protein in HGCC and HVEC after the action of KDR ASODN (n = 8, ¯x ± s)

action of KDR ASODN	A of HGCC		A of HVEC
action of KDR ASODN	mRNA	protein	mRNA	protein
Before (control)	0.35 ± 0.03	0.33 ± 0.02	0.37 ± 0.03	0.34 ± 0.03
After	0.16 ± 0.02^b	0.15 ± 0.02^b	0.16 ± 0.02^b	0.15 ± 0.02^b

^bP < 0.01, vs control.

Table 5 Different dose-time-effects of CMs of subconfluent and confluent HGCC on HVEC (n = 8, ¯x ± s)

CM volume fraction t/h cell confluent state	A of CM group/A of control group
	100%CM		80%CM		50%CM		30%CM		10%CM
	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent
24	2.38 ± 0.01^a	1.29 ± 0.00^a^b	2.70 ± 0.01^a	1.55 ± 0.02^a^b	2.21 ± 0.01^a	1.49 ± 0.02^a^b	2.10 ± 0.03^a	1.44 ± 0.01^a^b	1.92 ± 0.02^a	1.11 ± 0.01^a^b
48	1.60 ± 0.01^a	1.22 ± 0.01^a^b	1.54 ± 0.01^a	1.33 ± 0.02^a^b	1.38 ± 0.02^a	1.23 ± 0.02^a^b	1.37 ± 0.02^a	1.21 ± 0.01^a^b	1.31 ± 0.01^a	1.15 ± 0.02^a^b
72	0.89 ± 0.00	0.85 ± 0.00	0.99 ± 0.01	1.03 ± 0.01	1.07 ± 0.01^a	1.11 ± 0.01^a	1.27 ± 0.01^a	1.01 ± 0.00^b	1.01 ± 0.00	1.15 ± 0.01^a

^aP < 0.05 vs No-CM action group,

^bP < 0.05 vs subconfluent group.

Table 6 Different dose-time-effect of CMs of different preparing periods of confluent HGCC on HVEC (n = 8, ¯x ± s)

CM volume fraction t/h Preparing periods	A of CM group/A of control group
	100%CM		80%CM		50%CM		30%CM		10%CM
	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM
24	1.29 ± 0.01^a	1.38 ± 0.01^a^b	1.55 ± 0.02^a	1.39 ± 0.01^a^b	1.49 ± 0.01^a	1.38 ± 0.01^a^b	1.44 ± 0.02^a	1.30 ± 0.01^a^b	1.11 ± 0.01^a	1.00 ± 0.01^b
48	1.22 ± 0.01^a	1.11 ± 0.02^a^b	1.33 ± 0.01^a	1.14 ± 0.02^a^b	1.23 ± 0.01^a	1.03 ± 0.01^b	1.21 ± 0.01^a	1.03 ± 0.01^b	1.15 ± 0.01^a	1.02 ± 0.01^b
72	0.85 ± 0.01	0.78 ± 0.00	0.99 ± 0.01	0.92 ± 0.00	1.07 ± 0.02^a	1.14 ± 0.01^a^b	1.27 ± 0.01^a	1.20 ± 0.01^a^b	1.15 ± 0.01^a	1.16 ± 0.01^a

^aP < 0.05 vs No-CM action group,

^bP < 0.05 vs preparing for 24 hCM group.

Table 7 Effects of CMs of subconflunt and confluent HVEC on HGCC for 48 h (n = 8, ¯x ± s)

Volume fraction	Inhibitory rate of cell proliferation (%)
Volume fraction	CM of subconfluent HVEC	CM of confluent HVEC
100%CM	52.97 ± 0.01^a	31.62 ± 0.02^a^b
80%CM	54.26 ± 0.01^a	30.46 ± 0.01^a^b
50%CM	23.46 ± 0.01^a	19.00 ± 0.01^a^b
30%CM	21.70 ± 0.00^a	2.13 ± 0.01^b
10%CM	14.36 ± 0.00^a	1.61 ± 0.00^b

^aP < 0.05 vs No-CM action group;

^bP < 0.05 vs subconfluent group

Citation: Ren J, Dong L, Xu CB, Pan BR. The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8(4): 596-601
URL: https://www.wjgnet.com/1007-9327/full/v8/i4/596.htm
DOI: https://dx.doi.org/10.3748/wjg.v8.i4.596